INDICATION & USAGE

IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction after a previous dose of IXIARO, any other Japanese encephalitis vaccine,  or any component of IXIARO, including protamine sulfate a compound known to cause hypersensitivity reactions in some individuals is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO is considered.

Vaccination with IXIARO may not protect all individuals.  Individuals with a weakened immune system may have a diminished immune response to IXIARO.  Fainting may occur when receiving any injection, including IXIARO.  Tell your healthcare practitioner if you have a history of fainting from injections.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, muscle pain, and injection site pain and tenderness in adults.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  You should ask your healthcare practitioner for medical advice about adverse events.

For more information, please see the physician’s Prescribing Information and ask your healthcare practitioner about the risk and benefits of IXIARO.

    

INDICATION & USAGE

IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction after a previous dose of IXIARO, any other Japanese encephalitis vaccine,  or any component of IXIARO, including protamine sulfate  a compound known to cause hypersensitivity reactions in some individuals  is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO is considered.

Vaccination with IXIARO may not protect all individuals.  Individuals with a weakened immune system may have a diminished immune response to IXIARO.  Fainting may occur when receiving any injection, including IXIARO.  Tell your healthcare practitioner if you have a history of fainting from injections.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, muscle pain, and injection site pain and tenderness in adults.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  You should ask your healthcare practitioner for medical advice about adverse events.

For more information, please see the physician’s Prescribing Information and ask your healthcare practitioner about the risk and benefits of IXIARO.

    

 

 

Never underestimate
the power of a bite.

Never underestimate
the power of a bite.

Japanese encephalitis (JE) is a potentially devastating neurologic disease1

A traveler to any of 24 countries in Asia can be infected with JE virus,1 which is related to mosquito-borne Zika, dengue, yellow fever, and West Nile viruses.2 In rare cases, JE viral infection can result in encephalitis.1

Traveling to a country in Asia?
Ask your healthcare professional
about the risks and benefits of
IXIARO®

Japanese encephalitis (JE) is a potentially devastating neurologic disease1

A traveler to any of 24 countries in Asia can be infected with JE virus,1 which is related to mosquito-borne Zika, dengue, yellow fever, and West Nile viruses.2 In rare cases, JE viral infection can result in encephalitis.1

Traveling to a country in Asia?
Ask your healthcare professional
about the risks and benefits of
IXIARO®

Facts you should know before traveling to Asia.

CLICK TO EXPAND

KEY FACTS ABOUT JAPANESE ENCEPHALITIS

Japanese encephalitis
is not just in Japan


The Japanese encephalitis virus is endemic to 24 countries across Asia and Southeast Asia, as well as parts of the western Pacific.
1

Traveling to Asia
puts you at risk

Approximately 68,000 symptomatic cases of JE are estimated to occur each year in Asia.1

JE can result in
brain swelling and
stroke like symptoms1,4


Up to 50% of JE survivors have long-term serious complications and up to 30% who develop JE die.1,4

There is no specific
treatment for JE
1,3,4

Prevention is the best protection.1,3,4

CLICK TO EXPAND

KEY FACTS ABOUT JAPANESE ENCEPHALITIS

Japanese encephalitis is not just in Japan


The Japanese encephalitis virus is endemic to 24 countries across Asia and Southeast Asia, as well as parts of the western Pacific.
1

Traveling to Asia puts you at risk

Approximately 68,000 symptomatic cases of JE are estimated to occur each year in Asia.1

JE can result in brain swelling and stroke like symptoms1,4


Up to 50% of JE survivors have long-term serious complications and up to 30% who develop JE die.1,4

There is no specific treatment for JE1,3,4

Prevention is the best protection.1,3,4

One vaccine can help
protect them

Learn about IXIARO®

JE is a devastating yet
vaccine-preventable disease.
1,3

Centers for Disease Control
and Prevention (CDC)

Learn more about risk reduction strategies
and vaccination for travelers at risk.

What is IXIARO?®

CDC Recommends

One vaccine can help protect them

Learn about IXIARO®

JE is a devastating yet
vaccine-preventable disease.
1,3

What is Ixiaro?®

Centers for Disease Control and Prevention (CDC)

Learn more about risk reduction strategies and vaccination for travelers at risk.

CDC Recommends

Indication & Usage

IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction after a previous dose of IXIARO, any other Japanese encephalitis vaccine,  or any component of IXIARO,  including protamine sulfate a compound known to cause hypersensitivity reactions in some individuals is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO is considered.

Vaccination with IXIARO may not protect all individuals.  Individuals with a weakened immune system may have a diminished immune response to IXIARO.  Fainting may occur when receiving any injection, including IXIARO.  Tell your healthcare practitioner if you have a history of fainting from injections.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, muscle pain, and injection site pain and tenderness in adults.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  You should ask your healthcare practitioner for medical advice about adverse events.

For more information, please see the physician’s Prescribing Information and ask your healthcare practitioner about the risk and benefits of IXIARO.

 

 

 

Site is intended for travelers from the United States

1807-US-IX-044-1018 | 10/18 | Copyright © 2018 Valneva USA, Inc. All Rights Reserved.